
    
      This is a multicenter, long-term study of sirukumab (CNTO 136) that will be conducted in two
      groups of participants at the same time (parallel-group study). The maximum duration of
      participation in this study is 208 weeks, followed by approximately 16 weeks of safety and
      efficacy follow-up after the administration of the final study agent injection of sirukumab.
      Participant safety will be monitored throughout the study.
    
  